 BioVies pipeline indications represent a combined addressable market size of more than 100 billion with high unmet medical needs. Phase 2 trials have provided evidence to indicate that NE3107 may improve cognition and function in Alzheimers disease and dementia and may enhance motor control in Parkinsons disease. 